Testagen
Key Facts: Testagen
- Category
- Bioregulators
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical research, approved in Russia as supplement
- Administration
- Oral capsules or sublingual
- Typical Dose
- 10-20 mg daily
- Frequency
- Once or twice daily
- Duration
- 10-30 day cycles
Mechanism of Action
Testagen is proposed to act like the other ultrashort Khavinson peptides: enter the cell nucleus, bind short DNA sequences, and tune gene expression in its target tissue, here the testis. The hypothesized effect is supporting the cell's own programs for steroidogenesis (testosterone production by Leydig cells) and spermatogenesis, rather than acting as a hormone or a receptor agonist itself. This is a tissue-selectivity hypothesis from one research school, not an established pharmacological pathway. No specific receptor, human pharmacokinetics, or confirmed DNA-binding target for KEDG in testicular tissue has been independently demonstrated, so the mechanism should be read as theoretical.
Research Summary
The published evidence for Testagen is genuinely thin. The most concrete item is a small Russian clinical paper reporting that Testagen raised serum total testosterone in men with androgenic deficiency and chronic abacterial prostatitis (Rossikhin and colleagues, Problems of Endocrine Pathology, 2011), a study that has not been independently replicated and is hard to access in full. Beyond that, KEDG is mentioned within Khavinson-school discussions of organ-specific peptides and the broader peptide-DNA gene-regulation model, but there are no Western randomized controlled trials and no robust animal mechanistic series specific to this sequence. Marketing claims about boosting testosterone, fertility or thyroid function run well ahead of the data. Honest summary: one underpowered, unreplicated human report and a theoretical framework, which is not enough to call any effect established.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
10-20 mg daily
10-20 mg daily
Once or twice daily
Testicular bioregulator. Khavinson peptide for male reproductive health.
Research Dosingⓘ
Scientific studies
Doses from bioregulator supplement protocols
Doses from Studies
10-20 mg daily
Duration
10-30 day cycles
Administration
Oral capsules or sublingual
Timing & Administration
Best Time to Take
Morning on empty stomach
Once or twice daily
Food Recommendation
Take on empty stomach
Why This Timing?
Peptide bioregulators typically taken fasted for optimal absorption
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Limited safety data outside Russia
- ●Not FDA approved
References
- https://pubmed.ncbi.nlm.nih.gov/11713572/
- https://www.mdpi.com/1420-3049/26/22/7053
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9032300/
- https://link.springer.com/article/10.1134/S2079057013030065
Research This Peptide Further
Frequently Asked Questions
What does Testagen do?
Testagen is a synthetic Khavinson tetrapeptide (Lys-Glu-Asp-Gly, KEDG) marketed as a testicular bioregulator for male reproductive and hormonal support. It is one of the more obscure peptides in the family, with almost no peer-reviewed human data and no FDA or EMA approval. What exists is a single small Russian clinical report plus the general Khavinson gene-regulation theory, so confidence in any specific claim is low.
How does Testagen work?
Testagen is proposed to act like the other ultrashort Khavinson peptides: enter the cell nucleus, bind short DNA sequences, and tune gene expression in its target tissue, here the testis. The hypothesized effect is supporting the cell's own programs for steroidogenesis (testosterone production by Leydig cells) and spermatogenesis, rather than acting as a hormone or a receptor agonist itself. This is a tissue-selectivity hypothesis from one research school, not an established pharmacological pathway. No specific receptor, human pharmacokinetics, or confirmed DNA-binding target for KEDG in testicular tissue has been independently demonstrated, so the mechanism should be read as theoretical.
Is Testagen FDA approved?
No, Testagen is not currently FDA approved. Current status: Preclinical research, approved in Russia as supplement
What are the side effects of Testagen?
Reported side effects include: Generally well-tolerated, Limited safety data outside Russia, Not FDA approved. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Testagen?
Community-reported common dose: 10-20 mg daily (Once or twice daily). Range: 10-20 mg daily. Administration: Oral capsules or sublingual. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Testagen or used in similar applications.
Livagen
PreclinicalLivagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, or KEDA) from the family of short "peptide bioregulators" developed by Vladimir Khavinson's group in St. Petersburg, marketed in connection with liver and immune function. The proposed appeal is epigenetic: it has been reported to loosen tightly packed chromatin in aged cells, supposedly switching age-silenced genes back on. Evidence is limited to small laboratory and cell studies, mostly from one research group, with no clinical trials, so claims should be read with heavy skepticism.
BioregulatorsOvagen
PreclinicalOvagen is a synthetic ultra-short peptide, marketed as the tripeptide Glu-Asp-Leu (EDL), and grouped with the Khavinson-style "peptide bioregulators" promoted for liver and gastrointestinal support. Like its cousins in that family, it is claimed to act at the gene-expression level in a tissue-specific way. The honest picture: there is very little verifiable scientific data on Ovagen specifically, no clinical trials, and most of what is written about it comes from vendors rather than peer-reviewed research.
BioregulatorsCortagen
PreclinicalCortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro, AEDP) from Vladimir Khavinson's Russian peptide bioregulator program, designed as the defined-sequence stand-in for Cortexin, an older cattle brain cortex extract used in Russian neurology. It is studied mostly for nerve repair, brain function and aging, and it is not approved by the FDA or EMA. Real evidence is limited to animal experiments and Russian-institute work, with no Western randomized human trials.
BioregulatorsVesugen
PreclinicalVesugen is a synthetic tripeptide (Lys-Glu-Asp, or KED) from the Khavinson family of short peptide bioregulators, studied for vascular and neuroprotective effects. It is a research compound, not an approved drug, with no registered human clinical trials.
BioregulatorsChonluten
PreclinicalChonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) from the Khavinson bioregulator family, pitched as the lung and bronchial peptide, derived conceptually from the same program that produced Epitalon and Cortagen. It is researched for respiratory tissue and age-related lung decline, and it has no FDA or EMA approval. The evidence is essentially all preclinical or uncontrolled Russian clinical observation, with no randomized human trials.
BioregulatorsCrystagen
PreclinicalCrystagen is a synthetic tripeptide (Glu-Asp-Pro, or EDP) from the Khavinson family of short peptide bioregulators, studied as an immune and thymic regulator. It is a research compound, not an approved drug, with no registered human clinical trials. Note: many vendor pages list the wrong sequence; the correct one is Glu-Asp-Pro (EDP).
BioregulatorsWant updates on Testagen research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.